InVivoMAb anti-human PD-1 (CD279)
BE0188
ApplicationsNeutralisation/Blocking
Product group Antibodies
ReactivityHuman
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-human PD-1 (CD279)
- Delivery Days Customer7
- ApplicationsNeutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDJ116
- Concentration4-11 mg/ml
- Estimated Purity≥95% , Determined by SDS-PAGE
- HostMouse
- IsotypeIgG1
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC41116161
References
- Programmed death-1 controls T cell survival by regulating oxidative metabolism. Tkachev V et al., 2015 Jun 15, J ImmunolRead this paper
- The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Tsukahara T et al., 2015 Feb, Gene TherRead this paper
- Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Wang C et al., 2013 Apr, J Clin InvestRead this paper
- Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells. Singh A et al., 2012, PLoS OneRead this paper
- Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Rosignoli G et al., 2009 Jul, Clin Exp ImmunolRead this paper
- Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. Jurado JO et al., 2008 Jul 1, J ImmunolRead this paper
